Investigating how drug-resistant melanoma can become more sensitive to treatment
Directed Clonal Evolution of Drug Resistant BRAF Mutant Melanoma for Cross-Sensitization to MAPK Hyperactivation
This study is looking at ways to make melanoma cells that don't respond to current treatments more sensitive to new therapies, especially for patients with BRAF-mutant melanoma, by finding out how to target their weaknesses better.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Broad Institute, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11110287 on NIH RePORTER |
What this research studies
This research focuses on understanding how melanoma cells that have developed resistance to targeted therapies can be made more sensitive to treatment through a different approach. The study aims to explore the concept of 'context-dependent lethality,' where activating certain pathways in cancer cells may lead to their increased vulnerability. By examining the mechanisms of resistance in melanoma, particularly those involving the BRAF gene, the research seeks to identify new therapeutic strategies that could improve patient outcomes. Patients with BRAF-mutant melanoma may benefit from this innovative approach that aims to overcome existing treatment limitations.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with BRAF-mutant melanoma who have experienced resistance to current therapies.
Not a fit: Patients with melanoma that does not have BRAF mutations or those who have not undergone targeted therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with drug-resistant melanoma.
How similar studies have performed: Other research has shown promise in using similar approaches to overcome drug resistance in cancer treatment, indicating potential for success in this area.
Where this research is happening
Cambridge, United States
- Broad Institute, INC. — Cambridge, United States (Active)
Researchers
- Principal investigator: Cho, Eunice — Broad Institute, INC.
- Study coordinator: Cho, Eunice
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.